SUTRO BIOPHARMA, INC. Foreign Income Tax Expense (Benefit), Continuing Operations
SUTRO BIOPHARMA, INC. (STRO) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $2.50 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2025-03-13
- SUTRO BIOPHARMA, INC. foreign income tax expense (benefit), continuing operations for the quarter ending 2023-06-30 was $2.50M.
- SUTRO BIOPHARMA, INC. foreign income tax expense (benefit), continuing operations for the quarter ending 2022-12-31 was $0.00.
- SUTRO BIOPHARMA, INC. foreign income tax expense (benefit), continuing operations for the quarter ending 2022-09-30 was $0.00.
- SUTRO BIOPHARMA, INC. foreign income tax expense (benefit), continuing operations for fiscal 2022 was $2.50M.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 3 month | Foreign Income Tax Expense (Benefit), Continuing Operations 6 month | Foreign Income Tax Expense (Benefit), Continuing Operations 9 month | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-06-30 | $2.50M 10-Q · filed 2023-08-10 | $2.50M 10-Q · filed 2023-08-10 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $2.50M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $2.50M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |